Welcome to the TLDR Biotech newsletter!

Our aim is to (normally) be your one-stop source for biotech and pharma updates - all with one daily email.

Unfortunately I’m out sick - so it’s slimmer pickings today. Sorry 😢

We’ll be back with our usual biotech/pharma rodeo tomorrow!

BIOTECH MEMES
What’s your name again?

It’s ASGCT week in Baltimore - the greatest week of the year if you’re in the cell & gene therapy space.

We hope you like crabs!

DEEP DIVES & HOT TAKES
“The world is relying on the United States to get value-based drug pricing right“ - STAT News

For years, the U.S. has lead the word in biopharma innovation.

However, this came at a cost - higher drug prices domestically, while the rest of the world has benefited as medicines were approved and exported to new markets.

As drug pricing resentment rises within the U.S. (the Inflation Reduction Act as a prime example), there a tangible threat to this innovation ecosystem that we all depend on.

STAT News authors argue taking a full societal perspective that captures all costs and benefits is crucial for the U.S. to "get it right" on drug pricing while still incentivizing innovation.

Give the article a read here.

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍